AzTrials
AzTrials

Delirium, PostoperativeNCT06961994

rSVO₂ and Postoperative Delirium Prediction

An observational study of Delirium, Postoperative, run by Wonkwang University Hospital at 1 site in South Korea.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This prospective observational cohort study will enroll 300 patients aged ≥65 years undergoing elective noncardiac, non-neurosurgical procedures . Baseline rSVO₂ will be measured preoperatively using Near-Infrared Spectroscopy (NIRS). Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Delirium, Postoperative
How many people
300 participants
Where
1 siteSouth Korea
Study dates
29 Apr 2025to 5 Jun 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Older adults (≥65 years) undergoing elective noncardiac, non-neurosurgical surgery under general anesthesia. Patients were recruited from a university hospital in May 2025 and will be screened for eligibility based on cognitive ability, comorbidities, and frailty status.

  1. Inclusion Criteria: Age ≥ 65 years Scheduled for elective noncardiac, non-neurosurgical surgery under general anesthesia Expected postoperative hospital stay ≥ 2 nights Able to provide informed consent Capable of completing preoperative frailty and cognitive assessments
  2. Exclusion Criteria:

History of dementia, stroke, or cerebral tumors Chronic use of antipsychotic or anticholinergic medications Inability to complete cognitive assessments (e.g., language barrier, severe hearing/vision impairment) Current hemodialysis treatment Severe jaundice Missing baseline rSVO₂ data

Trial locations and contacts

1 site in 1 country.

South Korea1 site
  • Wonkwang University School of Medicine Hospital

    Iksan, Jeollabuk-do, 54538

Other trials in South Korea

About this study

Official title: Association of Baseline and Intraoperative rSVO₂ With Postoperative Delirium in Older Noncardiac and Non-neurosurgical Patients: A Prospective Observational Study

This prospective observational cohort study will enroll 300 patients aged ≥65 years undergoing elective noncardiac, non-neurosurgical procedures . Baseline rSVO₂ will be measured preoperatively using Near-Infrared Spectroscopy (NIRS). Intraoperative rSVO₂ will be monitored, recording the absolute lowest value and the rate of rSVO₂ decrease ([baseline - lowest]/baseline × 100). Postoperative delirium (POD) will be assessed daily for 7 days post-surgery using the Confusion Assessment Method (CAM). Frailty will be assessed using the Fried Frailty Phenotype. Logistic regression models, adjusted for age, ASA physical status, Charlson Comorbidity Index (CCI), hemoglobin, and intraoperative factors, will evaluate rSVO₂ metrics as predictors of POD. Linear regression will assess factors influencing the rate of rSVO₂ decrease. Pearson correlation and multivariate regression will analyze associations between POD risk factors. Receiver Operating Characteristic (ROC) analysis will compare the predictive accuracy of rSVO₂ metrics.

Read the detailed description

Study Design and Population This prospective observational cohort study will be conducted at Wonkwang University School of Medicine Hospital from May 2025, upon approval by the Institutional Review Board (IRB#2025-04-010-0021). Written informed consent will be obtained from all participants.

Patients aged ≥65 years scheduled for elective noncardiac, non-neurosurgical procedures (e.g., general, orthopedic, urologic, vascular) under general anesthesia with an expected hospital stay ≥2 nights will be included. Exclusion criteria will include dementia, stroke, cerebral tumors, chronic use of antipsychotics or anticholinergics, inability to perform cognitive assessments, or non-English first language.

Data Collection Baseline rSVO₂ Measurement: Baseline rSVO₂ will be measured preoperatively using the O3® Regional Oximetry system (Masimo Corp., Irvine, CA, USA). Sensors will be placed on the patient's forehead while seated, breathing room air, and resting. The stable rSVO₂ value after 60 seconds will be recorded.

Intraoperative rSVO₂ Monitoring: Intraoperative rSVO₂ will be continuously monitored using the same O3® system. Two metrics will be extracted: (1) the absolute lowest intraoperative rSVO₂ value, and (2) the rate of rSVO₂ decrease, calculated as:

$$\text{rate of rSVO₂ decrease (%)} = \frac{\text{Baseline rSVO₂} - \text{Absolute lowest intraoperative rSVO₂}}{\text{Baseline rSVO₂}} \times 100$$

Postoperative Delirium Assessment: POD will be assessed daily for 7 days post-surgery using the Confusion Assessment Method (CAM) [12]. A positive CAM on any day will indicate POD.

Postoperative Patient Destination: This will be recorded as transfer to the ICU or general ward post-surgery.

Covariates: These will include age, sex, American Society of Anesthesiologists (ASA) physical status, Charlson Comorbidity Index (CCI), preoperative hemoglobin, frailty, and intraoperative factors: vital signs (mean arterial pressure [MAP], heart rate), blood loss (mL), transfusion (yes/no), fluid administration (crystalloid and colloid volumes in mL), and vasopressor use (norepinephrine, phenylephrine, or none). Frailty will be assessed using the Fried Frailty Phenotype, defined by five criteria: unintentional weight loss (>4.5 kg in the past year), self-reported exhaustion, weak grip strength (measured by dynamometer), slow walking speed (timed 4.5-meter walk), and low physical activity (assessed via patient-reported activity levels) [16]. Patients meeting 0 criteria will be classified as robust, 1-2 as pre-frail, and ≥3 as frail. Frailty assessments will be conducted preoperatively by trained study personnel.

Sample Size Calculation

The sample size will be determined to address our primary objective of comparing the predictive performance of three rSVO₂ metrics (baseline rSVO₂, absolute lowest intraoperative rSVO₂, and rate of rSVO₂ decrease) for postoperative delirium (POD) in patients aged ≥65 years. Two complementary approaches will be used:

ROC AUC Comparison: From pilot data, baseline rSVO₂ yielded an AUC of 0.78, while the rate of rSVO₂ decrease had an AUC of 0.70-defining a minimum clinically relevant ΔAUC of 0.08. Using a two-sided α of 0.05, 80% power, and an anticipated POD incidence of 30% (event:non-event ratio ≈0.43:1), investigators will employ the power.roc.test() function in R's pROC package. This analysis indicates that 75 total patients (approximately 22 with POD and 53 without POD) will be sufficient to detect the specified AUC difference.

Multivariable Logistic Regression (EPV Rule): To ensure stable adjustment for covariates in multivariable models, investigators plan to include eight predictors: the three rSVO₂ metrics plus intraoperative blood loss, hypotension, vasopressor use, patient age, and ASA physical status. Applying the "events per variable" rule (minimum 10 events per predictor) will require 80 POD events. Assuming a 30% POD rate, this corresponds to 267 total patients (80 ÷ 0.30).

Finally, to accommodate an anticipated 10% rate of missing data or exclusions, investigators will inflate the larger of these estimates by dividing by 0.90, yielding a target enrollment of 297 patients, which will be rounded to 300 participants.

Statistical Analysis Continuous variables will be reported as mean (SD) or median [IQR], and categorical variables as number (%). Normality will be assessed using the Shapiro-Wilk test. Comparisons will use Student's t-test or Mann-Whitney U test for continuous variables and chi-square or Fisher's exact test for categorical variables. Logistic regression models, adjusted for age, ASA status, CCI, hemoglobin, frailty, and intraoperative factors, will evaluate rSVO₂ metrics as predictors of POD. Linear regression will assess factors influencing the rate of rSVO₂ decrease. Pearson correlation and multivariate regression will analyze associations between POD and risk factors. Receiver Operating Characteristic (ROC) curve analysis will compare the predictive accuracy of rSVO₂ metrics. A P-value <0.05 will be considered significant. Analyses will be performed using SPSS v29.0 (IBM, NY) and R v4.3.0 (R Foundation for Statistical Computing).

Medical subject headings
Emergence Delirium

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of Postoperative Delirium (POD)

    Postoperative delirium (POD) will be assessed daily for 7 days following surgery using the Confusion Assessment Method (CAM). The primary outcome is the occurrence of POD, defined as at least one positive CAM assessment during this period.

    Measured: Postoperative Days 1 to 7

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2025
  2. Study start29 Apr 2025
  3. Primary completion15 May 2025
  4. Study completion5 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06961994
Sponsor's protocol ID
Wonkwang UH16
Status last verified
May 2025
First submitted
29 Apr 2025
Last updated
6 Jun 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Zhu J, Wang W, Shi H. The Association between Postoperative Cognitive Dysfunction and Cerebral Oximetry during Geriatric Orthopedic Surgery: A Randomized Controlled Study. Biomed Res Int. 2021 Oct 19;2021:5733139. doi: 10.1155/2021/5733139. eCollection 2021.

    PubMed 34712732
  • Schoen J, Meyerrose J, Paarmann H, Heringlake M, Hueppe M, Berger KU. Preoperative regional cerebral oxygen saturation is a predictor of postoperative delirium in on-pump cardiac surgery patients: a prospective observational trial. Crit Care. 2011;15(5):R218. doi: 10.1186/cc10454. Epub 2011 Sep 19.

    PubMed 21929765

Questions about this trial

What is this clinical trial studying?

An observational study of Delirium, Postoperative, run by Wonkwang University Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Postoperative Delirium (POD) (time frame: Postoperative Days 1 to 7). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06961994, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in